Seeking Alpha

Johnson & Johnson (JNJ)

  • Jan. 30, 2013, 3:08 PM
    An orthopedic surgeon who helped design the all-metal hip implant that Johnson & Johnson (JNJ -0.4%) recalled in 2010 says the device wasn’t defective as he testified in the first of thousands of cases set to go to trial. “I have not used the term ‘defective’” the surgeon testified in a videotaped deposition. JNJ claims the implant was properly designed and the plaintiff's claim of elevated metal levels in his body can be traced to conditions including diabetes, high blood pressure and cholesterol, strokes and kidney cancer.
    | Jan. 30, 2013, 3:08 PM | 1 Comment
  • Jan. 25, 2013, 6:30 PM
    In its effort to shed its non-core businesses Johnson & Johnson (JNJ) is reportedly shopping its women's health unit. The unit, which competes with products from Procter & Gamble (PG), had world-wide sales of around $1.6B in 2012, which represents just a small percentage of JNJ's $67B in total sales over the same period. Still, with the right price tag, it's big enough to potentially pique the interest of private-equity buyers.
    | Jan. 25, 2013, 6:30 PM | 3 Comments
  • Jan. 23, 2013, 6:13 AM
    Johnson & Johnson (JNJ) knew that a metal hip-replacement implant was problematic in 2008, a year before the company halted production of the product and two years before recalling it, court documents show. The documents are part of a lawsuit whose opening arguments are due to start on Friday. Overall, J&J faces 10,000 suits over the implant, for which its estimated liability is over $1B.
    | Jan. 23, 2013, 6:13 AM | 2 Comments
  • Jan. 22, 2013, 10:01 AM
    J&J (JNJ -0.5%) is exploring the options for its Ortho Clinical Diagnostics (OCD) unit, including a divestiture if "it is determined that OCD could have greater potential as part of another organization whose focus is more closely aligned with its core strengths, or by operating as a stand-alone company."
    | Jan. 22, 2013, 10:01 AM | Comment!
  • Jan. 22, 2013, 8:18 AM
    More on J&J (JNJ -0.7%) Q4: expects 2013 EPS of $5.35-$5.45 vs consensus of $5.49. 2012 results boosted by upper respiratory over-the-counter products, international sales of Listerine, and U.S. sales of Neutrogena skin care products. Sales were hurt by generic competition for Levaquin and the manufacturing suspension at a third party supplier for Doxil. (PR)
    | Jan. 22, 2013, 8:18 AM | Comment!
  • Jan. 22, 2013, 8:03 AM
    More on Johnson & Johnson (JNJ) Q4: net profit excluding special items +7.9% to $3.4B; those items amount to $800M, and include "litigation accrual" and program costs associated with DePuy's recalled artificial hip. Acquisition of Synthes contributes 5.6% to sales growth. Domestic revenues +6.8%, international +8.9%. Shares -0.9%. (PR)
    | Jan. 22, 2013, 8:03 AM | Comment!
  • Jan. 22, 2013, 7:47 AM
    Johnson & Johnson (JNJ): Q4 EPS of $1.19 beats by $0.02. Revenue of $17.6B (+8% Y/Y) misses by $0.07B. Shares -1.3% premarket. (PR)
    | Jan. 22, 2013, 7:47 AM | Comment!
  • Jan. 22, 2013, 12:04 AM
    Notable earnings before Tuesday’s open: AMTD, CNI, CRBC, DAL, DD, EAT, FCX, FMER, JNJ, KSU, MTG, PETS, RF, SNV, TRV, VZ, WAT
    | Jan. 22, 2013, 12:04 AM | Comment!
  • Jan. 18, 2013, 2:56 PM
    Johnson & Johnson (JNJ) has reportedly offered to pay more than $200k per hip case, for a settlement that would top $2B. Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%) have been the subject of thousands of patient lawsuits for their metal-on-metal hip implants, which have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011.
    | Jan. 18, 2013, 2:56 PM | 3 Comments
  • Jan. 17, 2013, 7:44 PM
    The FDA is concerned whether several medical devices already on the market, such as electroconvulsive therapy devices for depression and emergency defibrillators, require additional evidence to prove they're safe. It's issued a safety advisory, saying patients with symptoms suggesting their devices aren't functioning properly should be considered for testing of possible metal ions in their bloodstream. Symptoms include: skin rashes, neurological changes such as hearing and vision impairment, and psychological status changes including depression.
    | Jan. 17, 2013, 7:44 PM | Comment!
  • Jan. 11, 2013, 5:52 AM
    An FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's (JNJ) canagliflozin treatment for Type 2 diabetes, although several of the panelists expressed concerns about its cardiovascular risks and its use for patients with moderate kidney disease. If authorized, analysts have forecast that canagliflozin could generate annual sales of $667M by 2016.
    | Jan. 11, 2013, 5:52 AM | Comment!
  • Jan. 8, 2013, 10:24 AM
    The FDA says Johnson & Johnson's (JNJ +0.1%) diabetes drug Invokana was effective at lowering a key measure of blood sugar, but the agency raised concerns about potential stroke and bone-related safety risks. The drug is due to be reviewed on Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The agency released its review of the product today in preparation for the panel meeting.
    | Jan. 8, 2013, 10:24 AM | Comment!
  • Jan. 7, 2013, 4:33 AM
    Jury selection is due to begin today in the first trial over Johnson & Johnson's (JNJ) Gynecare Prolift vaginal mesh implant, which a South Dakota woman says has caused her constant pain and has led to 18 operations. The complaint is one of 1,800 against Prolift, which J&J has said it will stop selling, while other manufacturers of similar implants also face lawsuits. (previous)
    | Jan. 7, 2013, 4:33 AM | Comment!
  • Jan. 4, 2013, 9:04 AM
    Johnson & Johnson (JNJ) is raised to Buy from Hold with an $82 price target, up from $75, at Deutsche Bank, which cites improving sales trends and benefits of diversification. Recent and new drugs should continue to drive pharma sales, and JNJ should continue to work through the McNeil Consent Decree and return consumer products to market. JNJ +0.6% premarket.
    | Jan. 4, 2013, 9:04 AM | 1 Comment
  • Jan. 3, 2013, 5:08 PM
    Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment.
    | Jan. 3, 2013, 5:08 PM | 1 Comment
  • Jan. 3, 2013, 11:43 AM
    Maybe less entertaining than Byron Wien, but almost surely more actionable is this list of predictions for 2013 from Ploutos. Among the ideas is outperformance by DELL and HPQ thanks to activist investors taking major stakes. A big purchase by Berkshire Hathaway (BRK.B) is being talked about, and Ploutos guesses it will be Cummins (CMI). Will JNJ give up its AAA rating to lever up and return cash to shareholders?
    | Jan. 3, 2013, 11:43 AM | 5 Comments
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.